近期,国家食品药品监督管理局组织对丁咯地尔进行了再评价并发布关于停止生产销售使用丁咯地尔的通知。通知指出,通过对近年来国内外研究资料的评价显示,丁咯地尔具有神经系统和心血管系统不良反应的风险,此类风险超过了其有限的临床治疗效益。根据《药品管理法》第四十二条和《药品管理法实施条例》四十一条,国家食品药品监督管理局决定停止丁咯地尔原料药和含丁咯地尔药品在我国的生产、销售 Recently, the CFDA conducted a reassessment of buflomedil and issued a notice on the cessation of the use of buflomedil for its production and sales. The circular pointed out that the evaluation of research data both at home and abroad in recent years shows that buflomedil poses a risk of adverse reactions to the nervous system and cardiovascular system and that such risks outweigh the limited clinical benefits. According to Article 42 of the Drug Administration Law and Article 41 of the Regulations for the Implementation of the Drug Administration Law, SFDA decided to stop the production of buflomedil bulk drugs and buflomedil containing drugs in China, Sales